The constellation of histopathologic lesions that characterize alcoholic and nonalcoholic steatohepatitis has been well described and has served as the basis for clinical diagnosis, natural history studies, and experimental models for analyses of etiopathogenesis. The lesions common to both entities include,...
treatment for non-alcoholic fatty liver diseasetreatment for non-alcoholic steatohepatitisNon-alcoholic fatty liver disease (NAFLD) has become the most common etiology for abnormal aminotransferase levels and chronic liver disease. Its growing prevalence is largely linked to the presence of metabolic ...
Our understanding of nonalcoholic fatty liver disease pathophysiology continues to advance rapidly. Accordingly, the field has moved from describing the clinical phenotype through the presence of nonalcoholic steatohepatitis (NASH) and degree of fibrosis to deep phenotyping with a description of associated...
Non-alcoholic fatty liver disease (NAFLD) is likely the most common cause of liver disease in adults as well as in children and adolescents. Its occurrence is closely associated with obesity and insulin resistance. NAFLD may lead to non-alcoholic steatohepatitis (NASH) with possible evolution towar...
awelcome to China 中国へようこそ[translate] a6.6.9 Bypasses within the filter should always be avoided (e.g. by double seals). 6.6.9 应该总避免旁路在过滤器之内 (即。 由双重封印)。[translate] aNon-alcoholic steatohepatitis 非酒精steatohepatitis[translate]...
Non-alcoholic fatty liver disease (NAFLD) includes a range of hepatic manifestations, starting with liver steatosis and potentially evolving towards non-alcoholic steatohepatitis (NASH), cirrhosis or even hepatocellular carcinoma. NAFLD is a major health burden, and its incidence is increasing worldwide...
Nonalcoholic steatohepatitis (NASH), unlike simple steatosis, is a potentially progressive disease. Various types of drugs have been explored for the treatment of NASH. We reviewed the various therapies available, with particular emphasis on their efficacy for the improvement of hepatic fibrosis. Treat...
Review article: the treatment of non-alcoholic steohepatitis with thiazolidinediones. Aliment Pharmacol Ther 2005; 22: 897–905H.REYNAERT, A.GEERTS, J.HENRION. (2005) Review article: the treatment of non-alcoholic steatohepatitis with thiazolidinediones. Alimentary Pharmacology and Therapeutics 22 :...
Metabolic dysfunction-associated steatohepatitis (MASH): This used to be known as nonalcoholic steatohepatitis (NASH). It's the advanced stage of FLD and means you have inflammation in your liver. The inflammation and liver cell damage that happen with MASH can cause serious problems such as hepa...
At present, compared with high-dose ursodeoxycholic acid(UDCA) and other bile acid drugs in the treatment of NAFLD, low-dose obeticholic acid has more advantages and exploration value in the treatment of NAFLD. Key words: Non-alcoholic fatty liver disease(NAFLD) Obeticholic acid Farnesoid X ...